Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

Ascierto, PA and Grimaldi, AM and Anderson, AC and Bifulco, C and Cochran, A and Garbe, C and Eggermont, AM and Faries, M and Ferrone, S and Gershenwald, JE and Gajewski, TF and Halaban, R and Stephen Hodi, F and Kefford, R and Kirkwood, JM and Larkin, J and Leachman, S and Maio, M and Marais, R and Masucci, G and Melero, I and Palmieri, G and Puzanov, I and Ribas, A and Saenger, Y and Schilling, B and Seliger, B and Stroncek, D and Sullivan, R and Testori, A and Wang, E and Ciliberto, G and Mozzillo, N and Marincola, FM and Thurin, M (2014) Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Journal of Translational Medicine, 12 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (776kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

The fourth "Melanoma Bridge Meeting" took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent research in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, like BRAF and MEK inhibitors, as well as other signaling pathways inhibitors, are being tested in metastatic melanoma either as monotherapy or in combination, and have yielded promising results. Improved survival rates have also been observed with immune therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demonstrate clinical benefit in melanoma as well. This meeting's specific focus was on advances in targeted therapy and immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment response was an integral part of the meeting. Significant consideration was given to issues surrounding the development of novel therapeutic targets as further study of patterns of resistance to both immunologic and targeted drugs are paramount to future drug development to guide existing and future therapies. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Ascierto, PA Grimaldi, AM Anderson, AC Bifulco, C Cochran, A Garbe, C Eggermont, AM Faries, M Ferrone, S Gershenwald, JE Gajewski, TF Halaban, R Stephen Hodi, F Kefford, R Kirkwood, JM kirkwood@pitt.edu KIRKWOOD Larkin, J Leachman, S Maio, M Marais, R Masucci, G Melero, I Palmieri, G Puzanov, I Ribas, A Saenger, Y Schilling, B Seliger, B Stroncek, D Sullivan, R Testori, A Wang, E Ciliberto, G Mozzillo, N Marincola, FM Thurin, M
Date:	1 January 2014
Date Type:	Publication
Journal or Publication Title:	Journal of Translational Medicine
Volume:	12
Number:	1
DOI or Unique Handle:	10.1186/s12967-014-0277-z
Schools and Programs:	School of Medicine > Dermatology
Refereed:	Yes
Date Deposited:	21 Dec 2016 20:46
Last Modified:	19 Jun 2021 10:55
URI:	http://d-scholarship.pitt.edu/id/eprint/29476

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item